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Abstract
Background: Treatment of hypertension reduces incidence of stroke, myocardial infarction and heart failure
perhaps partly by controlling different metabolic parameters. There is limited information regarding the changes in
potassium, sodium, weight, cholesterol and glucose levels in patients using anti-hypertensives. This study aimed to
determine changes in potassium, sodium, glucose, cholesterol, weight, urea and urate levels in patients using
anti-hypertensives. Furthermore, to describe these changes and differences between the atenolol, hydrochlorothiazide
plus amiloride and placebo arms of the Medical Research Council (MRC) elderly randomised controlled trial.
Methods: Patients were randomly allocated to one of the three treatment arms. Measurements were taken at baseline,
end of year one and end of year two in 4396 subjects. Linear Mixed Models (LMM) were used to determine
the longitudinal profiles of sodium, potassium, weight, cholesterol, glucose, urea and urate. Estimates of changes
within groups and difference between groups were obtained.
Results: Patients randomised to receive hydrochlorothiazide + amiloride experienced a significantly greater mean
reduction in potassium, sodium and weight compared to placebo at end of year one - mean differences in change −0.
18 mmol/L, (95 % CI: −0.21, −0.15); −1.45 mmol/L, (95 % CI: −1.62, −1.29) and −0.46 kgs (95 % CI: −0.73, −0.
20) respectively, and greater increases in cholesterol, urea and urate - mean differences in change 0.16 mmol/L,
(95 % CI: 0.10,0.22); 0.77 mmol/L, (95 % CI: 0.68, 0.87) and 53.10 μmol/L, (95 % CI: 49.35, 56.85) respectively. Changes
were in the same direction but smaller in the atenololarm except for potassium and weight (increases). No group
differences in glucose were found.
Conclusion: Results were in line with expectation except for lack of change in glucose in the hydrochlorothiazide +
amiloride arms.
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Background
Hypertension is present in at least 25 % of adults under
the age of 50, and 50 % of those who are older [1]. It is
responsible for 13 % of global deaths, 55 % of cerebro-
vascular disease, 45 % of heart disease and 61 % of car-
diovascular deaths, and further linked to incidences of
kidney disease, affecting high, low and middle-income
countries [2]. Those living with uncontrolled hyperten-
sion grew from 605 million to 978 million worldwide be-
tween 1980 and 2008, making it highly relevant to
contemporary medical practice [3].
Treatments for hypertension - which aim to reach and
maintain acceptable blood pressure levels (<140/
90 mmHg) - include angiotensin converting enzyme in-
hibitors (ACEs), angiotensin receptor blockers (ARBs),
calcium channel blockers (CCBs), diuretics and beta-
blockers. In the UK, recommended first line treatments
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have changed over time; CCBs are currently favoured as
first line treatment for those aged over 55 years and for
some ethnic groups at all ages, but thiazide or thiazide-
like diuretics may also be recommended as first- or
second-line therapy in certain cases [1, 4]. In the US, the
recommendations for first line treatments in the 2014 -
8thJoint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure
(JNC) report continue to include thiazide type diuretics
as well as ACEs, ARBs and CCBs [5]. Diuretics were
found to be the most commonly prescribed drug in
2009–2010 in the US National Health and Nutrition
Examination Survey population with the most common
type being thiazide type diuretics [6, 7]. A thiazide diur-
etic, hydrochlorothiazide + amiloride, was used in the
UK MRC trial which we report on in this paper; this
drug remains in common use at the time of writing [8].
Thiazide diuretics lower blood pressure by blocking
reabsorption of sodium ions in the distal renal convo-
luted tubule and therefore draw water to be excreted as
urine. This lowers blood volume leading to a reduction
in cardiac output, and a reduction in peripheral resist-
ance [1, 9]. Increased excretion of sodium, and perhaps
some weight loss, are expected [10, 11]. However, their
use is also associated with increased excretion of potas-
sium- in extreme cases causing hypokalaemia - due to
an increased exchange rate in potassium for sodium
[12–16]. To counteract this, the use of a potassium spar-
ing diuretic – on their own only weakly diuretic – may
be used in combination.
Thiazide diuretics are known to increase serum urate
concentrations, potentially increasing the occurrence of
gout and gouty attacks and may also lead to low concen-
trations of urea [8, 17–19]. Moreover, the use of thiazide
diuretics - and beta-blockers - is known to affect glucose
homeostasis through potential β-pancreatic cell damage;
they are associated with undesirable metabolic changes
including decreased insulin secretion and sensitivity and
decreased glucose tolerance [20, 21]. By causing in-
creased excretion of potassium, thiazides can worsen
glucose intolerance as low potassium inhibits insulin se-
cretion [22], although there is limited evidence to sup-
port this [23]. However, this leads to an aggravated
metabolic profile and an increased risk of new-onset dia-
betes mellitus [21, 24].
The 1980s UK MRC hypertensive trial among patients
aged over 65 compared three treatment regimens: hy-
drochlorothiazide combined with potassium sparing
amiloride, the beta blocker atenolol and placebo [24].
Hydrochlorothiazide + amiloride were shown to be more
effective than atenolol for prevention of stroke and MI,
as also found elsewhere [20, 24–26]. A report on blood
pressure reduction in the treatment arms was also pub-
lished [27] and recently updated [26]. But, although data
on sodium, potassium, cholesterol, glucose, urate, urea
and weight were collected for two years, there has been
no report on how these parameters were affected. The
continued use of hydrochlorothiazide makes these data
highly relevant to current practice as does the data from
the atenolol group. Beta-blockers block the action of cat-
echolamines on portions of the sympathetic nervous sys-
tem (those being the beta-adrenergic or β1 and β2
receptors) [28], in order to reduce heart rate, cardiac
contractive force, and cardiac output [29]. Although they
are no longer recommended by NICE as a first-line
treatment option [1, 30], beta-blockers are known to
have equal or greater effectiveness in the young com-
pared with other anti-hypertensives [20, 25].
The objective of this work was to see how weight, po-
tassium, sodium, cholesterol, glucose, urea and urate
levels changed over time and whether the changes were
different in the three arms. As noted, the results of the
study in terms of blood pressure changes, mortality and
cardio/cerebrovascular morbidity have already been pub-
lished [24, 26, 27].
Methods
Data source and type
The data come from a Medical Research Council (UK)
sponsored trial of anti-hypertensive medications in older
adults which concluded in 1990 [24]. This was a ran-
domized, placebo controlled, single blind trial (RCT)
with two active arms (atenololand hydrochlorothiazide +
amiloride) and a placebo arm. There were 4396 patients
enrolled in total and they were followed for up to five
years post-enrolment. Patients in diuretic arm received
hydrochlorothiazide 50 mg plus amiloride 5 mg daily.
However, due to metabolic disturbances observed after
one year, all patients were transferred to a lower dose
(hydrochlorothiazide 25 mg plus amiloride 2.5 mg). In
the beta-blocker arm, patients received atenolol 50 mg
once daily. If patients did not achieve target blood pres-
sure after 12 weeks in this arm, the dose was increased
(atenolol 100 mg); the calcium channel blocker nifedi-
pine (doses up to 20 mg daily) and other supplementary
drugs could be used if further control was needed [24].
The patients were seen by the research doctors and
nurses at regular intervals in order to monitor their
blood pressure and other parameters including weight,
potassium, sodium, cholesterol, glucose, urea and urate
levels. The latter set were measured at recruitment and
end of years one and two of follow-up; unfortunately,
there is no information available on the measurement
protocol for these parameters.
Missing data
Although the measurement schedule was fixed, not all
patients have all the planned measurements owing to
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drop-out from the trial and because some patients may
have died. The analyses here have been done on avail-
able data only but we conducted preliminary analyses to
see whether those who later had missing data were dif-
ferent at baseline from those who did not.
Statistical analysis
Changes over the first two years of the trial in potassium,
sodium, glucose, weight and cholesterol were determined
and compared between the randomised treatment arms
regardless of adherence to treatment, i.e. according to the
principle of Intention-To-Treat (ITT) analysis. The main
analyses were based on fitting a Linear Mixed Models
(LMM) to the data with time treated as a categorical vari-
able and with an unstructured covariance structure; to
study differences over time between groups, the model in-
cluded group*time ‘interaction’ terms. Estimates of mean
change within groups – and their Standard Errors (SE) -
and differences between groups (hydrochlorothiazide +
amiloride versus placebo, atenolol versus placebo and hy-
drochlorothiazide + amiloride versus atenolol) were ex-
tracted from these models. The advantage of this analysis
approach over use of, say, paired and unpaired t-tests is
that data from all patients can be used including from pa-
tients who had an incomplete data schedule. The variance
components of the LMM models were set up to allow for
the fact that within-group patient variability of most
parameters tended to increase over time. The main
focus of the analysis is the comparison of changes in
the active treatment groups compared to each other
and the placebo group.
Results
Background characteristics of patients
The 4396 patients enrolled in the trial were randomised
to receive hydrochlorothiazide + amiloride (24.6 %),
atenolol (25.1 %) or placebo (50.3 %). The median pa-
tient age (years) recorded during recruitment was 70
(ranging from 65 to 75) and 58.2 % (2,560) were female.
At baseline, the mean glucose level amongst patients
was 3.35 mmol/L; the average weight 70.16kgs; the mean
potassium level 4.22 mmol/L; the mean sodium level
141.59 mmol/L; the mean cholesterol level 6.47 mmol/L,
the mean urea 5.91 mmol/L and mean urate level
338.56 μmol/L. The baseline characteristics are com-
pared between randomisation groups in Table 1; there
are no important differences.
Completed measurements per patient
Table 2 shows the number of measurements recorded
per person at the three visits for various parameters.
The majority of participants 3936 (89.5 %) had all 3
measurements taken for weight. Nearly three quarters of
patients had all measurements recorded for sodium, po-
tassium and urate. Almost two thirds of patients had all
measurements for cholesterol, urea and glucose. The
percentage of patients who died over the two years in
the hydrochlorothiazide + amiloride arm was 12.4 %, in
the atenolol arm 15.2 %, and in the placebo arm 14.2 %,
which explains some of the missing data. Sixty-two pa-
tients (1.4 %) had died by end of year one.
Changes in outcome variables over time
Additional file 1: Table S1 shows the mean and SD of
the measures for all treatment groups combined at each
time point based on the available data for each visit; the
numbers of patients vary between time points. These
data show little change (less than 0.1 SD) in mean
weight, glucose, cholesterol, or potassium over the first
two years of the trial. The mean sodium decreased in
the first year while urea and urate levels increased.
Table 1 Baseline characteristics of the study population (n = 4396)
Characteristics Treatment group
Hydrochlorothiazide + amiloride Atenolol Placebo
Number of patients enrolled 1081 (24.6) 1102 (25.1) 2213 (50.3)
Male, n (%) 454 (42.0) 456 (41.4) 926 (41.8)
Age, years 70.4 ± 2.7 70.3 ± 2.8 70.3 ± 2.7
Weight, kg 70.1 ± 12.4 70.4 ± 12.5 70.0 ± 12.6
Serum potassium, mmol/L‡ 4.2 ± 0.4 (n = 1046) 4.2 ± 0.4 (n = 1072) 4.2 ± 0.4 (n = 2160)
Serum sodium, mmol/L‡ 141.6 ± 2.0 (n = 1055) 141.6 ± 2.0 (n = 1083) 141.6 ± 2.0 (n = 2173)
Glucose, mmol/L‡ 3.4 ± 0.7 (n = 999) 3.4 ± 0.7 (n = 1025) 3.4 ± 0.7 (n = 2051)
Serum cholesterol, mmol/L‡ 6.5 ± 1.3 (n = 1054) 6.5 ± 1.2 (n = 1075) 6.4 ± 1.2 (n = 2154)
Serum urea, mmol/L‡ 6.0 ± 1.4 (n = 1036) 5.9 ± 1.4 (n = 1066) 5.9 ± 1.3 (n = 2128)
Serum urate, μmol/L‡ 341.8 ± 70.5 (n = 1002) 336.8 ± 71.4 (n = 1030) 337.8 ± 70.5 (n = 2053)
‡Sample sizes for those with data on each measure are also shown
Damian et al. BMC Cardiovascular Disorders  (2016) 16:188 Page 3 of 9
Except for weight, the SDs of the parameters tended to
increase over time.
Comparisons between estimates of change over time
between treatment groups
All available data for each parameter were included in
the LMM statistical models. The models was used to es-
timate within-patient changes over time and to test
whether these changes differed significantly between
groups; these results are presented in Table 3. In consid-
ering results for each outcome, it is important to allow
for any changes over time which might have occurred
regardless of active treatment; hence changes in the pla-
cebo group are also shown.
Potassium
In the placebo arm, the change in the mean potassium
level in year one compared to year zero was close to
zero but there was a marginally significant increase in
year 2 compared to year 1 of 0.02 mmol/L. At the end
of year 1, patients in hydrochlorothiazide + amiloride
arm had a statistically significant mean change in potas-
sium level of −0.18 mmol/L compared to year zero,
which was also significantly different from the (near
zero) change in the placebo arm: (95 % CI for mean dif-
ference in changes: −0.21, −0.15). Furthermore, there
was a significant change of 0.04 mmol/L in year two
compared to year one in the hydrochlorothiazide +
amiloride group, but this was not statistically significant
compared to the placebo group change in the same
period: (mean difference in changes 0.02 mmol/L, 95 %
CI: −0.01, 0.07). In the atenolol arm, there was a statisti-
cally significant increase in the mean potassium level in
year one compared to year zero of 0.07 mmol/L and a
non-significant change of −0.03 mmol/L in year two
compared to year one. The differences between ateno-
lol arm and placebo arm in the changes in potassium
in year 1 vs. year 0 and in year 2 vs. year 1 were sta-
tistically significant: mean difference in changes of
0.07 mmol/L, 95 % CI: (0.04, 0.11) and −0.5 mmol/L,
95 % CI: −0.08, −0.01) respectively. The differences
between the hydrochlorothiazide + amiloride arm
change (D) and atenolol arm change (B) were statistically
significant: in year 1 vs. year 0, the mean difference (D-B)
was −0.25 mmol/L, 95 % CI: (−0.29, −0.22), while for year
2 vs. year 1 changes, the mean difference (D-B) was
0.07 mmol/L, 95 % CI: (0.03, 0.11).
Sodium
In the placebo group, the change in the mean sodium level
in year one compared to year zero was −0.19 mmol/L and
in year 2 compared to year 1 was close to zero. The
Table 2 Number of measurements recorded per patient for
each parameter (total patients = 4396)
Parameter Number of measurements recorded
n (%)
None 1 2 3
Weight, kg 5 (0.1) 0 (0.0) 455 (10.4) 3936 (89.5)
Serum potassium, mmol/L 21 (0.5) 494 (11.2) 636 (14.5) 3245 (73.8)
Serum sodium, mmol/L 15 (0.3) 489 (11.1) 598 (13.6) 3294 (74.9)
Glucose, mmol/L 45 (0.3) 561 (12.8) 913 (20.8) 2877 (65.5)
Serum cholesterol, mmol/L 22 (0.5) 490 (11.2) 652 (14.8) 3232 (65.7)
Serum urea, mmol/L 45 (1.0) 560 (12.7) 904 (20.6) 2887 (65.7)
Serum urate, μmol/L 18 (0.4) 512 (11.6) 737 (16.7) 3129 (71.2)
Table 3 Mean (SE of mean) within-patient changes over time by treatment group
Changes Potassium Sodium Glucose Cholesterol Weight Urea Urate




−0.00 (0.01) −0.19 (0.05)** −0.00 (0.02) −0.03 (0.02) −0.45 (0.08)** 0.08 (0.03)** 3.35 (1.09)**
Yr2 vs.
Yr1




−0.18 (0.01)*,** −1.64 (0.07)*,** 0.03 (0.03) 0.13 (0.02)*,** −0.91 (0.11)*,** 0.85 (0.04)*,** 56.45 (1.57)*,**
Yr2 vs.
Yr1




0.07 (0.01)*,** −0.78 (0.07)*,** −0.01 (0.03) 0.04 (0.02)* 0.05 (0.11)* 0.62 (0.04)*,** 43.00 (1.55)*,**
Yr2 vs.
Yr1
−0.03 (0.01)* −0.14 (0.08) 0.03 (0.03) 0.08 (0.03)** −0.03 (0.11) 0.21 (0.05)** 4.81 (1.68)**
*Indicates P <0.05 and refers to test for difference in change in active treatment group compared to placebo group
**Indicates P <0.05 and refers to within-patient changes over time in each group
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former change was statistically significant (95 % CI:
−0.09, −0.29). Compared to year zero, at the end of
year 1, patients in hydrochlorothiazide + amiloride
arm had a statistically significant mean change in so-
dium level of −1.64 mmol/L. This fall in the hydro-
chlorothiazide + amiloride group was significantly
greater than in the placebo group (mean difference in
changes −1.45 mmol/L, 95 % CI: −1.62, −1.29). There
was a change of 0.14 mmol/L in year two compared
to year one in the hydrochlorothiazide + amiloride
group; this change was not statistically significant and
not significantly greater compared to the placebo
group (mean difference in changes 0.14 mmol/L, 95 % CI:
−0.04, 0.33). In the atenolol arm, there was a statistically
significant change in the mean sodium level in year
one compared to year zero of −0.78 mmol/L and a
non-significant change of −0.14 units in year two
compared to year one. The difference in changes in
sodium in atenolol group compared to placebo group
was statistically significant (mean difference in
changes −0.59 mmol/L, 95 % CI: −0.76, −0.42) for
year 1 vs. year 0 but not significant for year 2 vs. year
1 (mean difference in changes −0.13 mmol/L, 95 %
CI: −0.32, −0.06). Also, the difference between the hy-
drochlorothiazide + amiloride arm and atenolol arm
changes were statistically significant but in different
directions in the two periods: in year 1 vs. year 0, the
mean difference (D-B) was −0.87 mmol/L, 95 % CI:
(−1.07, −0.67) while in year 2 vs. year 1, it was
0.27 mmol/L, 95 % CI: (0.05, 0.50).
Glucose
The change in the mean glucose level in year one com-
pared to year zero in the placebo arm was close to zero
and 0.05 mmol/L in year 2 compared to year 1. The latter
change was statistically significant (95 % CI: 0.01, 0.09).
Patients in the hydrochlorothiazide + amiloride arm had a
non-significant mean change in glucose level of
0.03 mmol/L in year one compared to year zero and
0.04 mmol/L in year two compared to year one. The differ-
ences in the changes in glucose in year 1 vs. year 0 and year
2 vs. year 1 between hydrochlorothiazide + amiloride arm
and placebo arm were not statistically significant (. mean
difference in changes 0.03 mmol/L, 95 % CI: −0.04, 0.09)
and −0.01 mmol/L, 95 % CI: −0.08, 0.06) respectively. In
the atenolol arm, there was a non-significant change in the
mean glucose level in year one compared to year zero of
−0.01 mmol/L and 0.03 mmol/L in year two compared to
year one. The differences in the changes in glucose in year
1 vs. year 0 and year 2 vs. year 1 between atenolol arm and
placebo arm were not statistically significant i.e. mean dif-
ference in changes of −0.01 mmol/L, 95 % CI: −0.07, 0.05)
and (−0.02 mmol/L), (95 % CI) (−0.08, 0.05) respectively.
Likewise the difference between the hydrochlorothiazide +
amiloride arm and atenolol arm changes (D-B) were not
statistically significant: 0.04 mmol/L, 95 % CI: (−0.04, 0.11)
in year 1 vs. year 0, and 0.01 mmol/L, 95 % CI: (−0.07,
0.09) in year 2 vs. year 1.
Cholesterol
In the placebo arm, the mean change in cholesterol level
in year one compared to year zero was −0.03 mmol/L
and in year 2 compared to year 1 was 0.07 mmol/L. The
latter change was statistically significant (95 % CI: 0.03,
0.11). Compared to year zero, at the end of year 1, pa-
tients in hydrochlorothiazide + amiloride arm had a sta-
tistically significant mean change in cholesterol level of
0.13 mmol/L. This change was significantly different
compared to the placebo group change (mean difference
in changes 0.16 mmol/L, 95 % CI: 0.10, 0.22). There was
a non-significant change of −0.01 mmol/L in year two
compared to year one in the hydrochlorothiazide +
amiloride group, but this was significantly different from
the placebo group whose cholesterol has increased in
this period (mean difference in changes −0.08 mmol/L,
95 % CI: −0.15, −0.02). In the atenolol arm, there was a
non-significant change in the mean cholesterol level in
year one compared to year zero of 0.04 mmol/L and a
statistically significant change of 0.08 mmol/L in year
two compared to year one. The difference in changes in
cholesterol levels between the atenolol group and the
placebo group was statistically significant in year 1 vs.
year 0 (mean difference in changes 0.07 mmol/L, 95 %
CI: 0.02, 0.13) but not significant in year 2 vs. year 1
(mean difference in changes 0.01 mmol/L, 95 % CI:
−0.05, 0.07). Also, the difference between the hydrochlo-
rothiazide + amiloride arm and atenolol arm changes
were statistically significant but in different directions: in
year 1 vs. year 0, the mean difference (D-B) was
0.08 mmol/L, 95 % CI: (0.02, 0.15) while in year 2 vs.
year 1, it was −0.09 mmol/L, 95 % CI: (−0.17, −0.02).
Weight
In the placebo arm, there were statistically significant
change in mean weight in year one compared to year
zero −0.45 kgs 95 % CI (−0.29, −0.60) and in year 2
compared to year 1: −0.23 kgs 95 % CI: (−0.38, −0.09).
Patients in hydrochlorothiazide + amiloride arm had a
statistically significant mean change in weight of −0.91
kgs in year one compared to year zero and −0.26 kgs in
year two compared to year one. The differences between
hydrochlorothiazide + amiloride arm and placebo arm in
the changes in weight in year 1 vs. year 0 was statistically
significant (mean difference in changes of −0.46 kgs,
95 % CI: −0.73, −0.20) but not in year 2 vs. year 1, (mean
difference in changes of −0.03 kgs, 95 % CI: −0.29, 0.23).
In the atenolol arm, there were non-significant changes
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in mean weight in year one compared to year zero of
0.05 kgs and of −0.03 kgs in year two compared to year
one. The differences in the changes in weight between
atenolol arm and placebo arm in year 1 vs. year 0 was
statistically significant (mean difference in changes of
0.50 kgs, (95 % CI: 0.23, 0.76) but not significant be-
tween year 2 vs. year 1 (mean difference in changes of
0.20 kgs, 95 % CI: −0.06, 0.46). The difference between
the hydrochlorothiazide + amiloride arm and atenolol
arm changes in weight was statistically significant in the
first period - mean difference (D-B) of −0.96 kgs, 95 %
CI: (−1.27, 0.65) but not in the second - mean difference
(D-B) of −0.23 kgs, 95 % CI: (−0.57, 0.10).
Urea
In the placebo arm, there were statistically significant
mean changes in urea in year one compared to year zero
- 0.08 mmol/L (95 % CI: 0.03, 0.14) - and in year 2 com-
pared to year 1 – 0.16 mmol/L (95 % CI: 0.10, 0.22). Pa-
tients in the hydrochlorothiazide + amiloride arm had a
statistically significant mean change in urea of
0.85 mmol/L (95 % CI: 0.78, 0.93) in year one compared
to year zero and of 0.13 mmol/L (95 % CI: 0.03, 0.22) in
year two compared to year one respectively. The differ-
ences in the changes in urea between hydrochlorothia-
zide + amiloride arm and placebo arm in year 1 vs. year
0 was statistically significant (mean difference in changes
of 0.77 mmol/L, (95 % CI: 0.68, 0.87) but not statistically
significant in year 2 vs. year 1 (mean difference in
changes of −0.03 mmol/L, 95 % CI: −0.15, 0.08). In the
atenolol arm, there were statistically significant changes
in the mean urea in year one compared to year zero of
0.62 mmol/L (95 % CI: 0.54, 0.70) and 0.21 mmol/L
(95 % CI: 0.11, 0.302) in year two compared to year one.
The differences in the changes in urea between atenolol
arm and placebo arm in year 1 vs. year 0 was statistically
significant (mean difference in changes of 0.54 mmol/L,
95 % CI: 0.44, 0.63) but non-significant between year 2
vs. year 1 (. mean difference in changes of 0.05 mmol/L,
95 % CI: −0.07, 0.16). The difference between the hydro-
chlorothiazide + amiloride arm and atenolol arm changes
was statistically significant for year 1 vs. year 0 - mean
difference (D-B) was 0.24 mmol/L, 95 % CI: (0.13, 0.35 -
but not in year 2 vs. year 1 - mean difference (D-B) was
−0.08 mmol/L, 95 % CI: (−0.22, 0.05).
Urate
In the placebo group, the changes in urate in year one
compared to year zero was 3.35 μmol/L (95 % CI: 1.21,
5.49) and in year 2 compared to year 1 was 3.89 μmol/L
(95 % CI: 1.59, 6.19). Patients in the hydrochlorothiazide
+ amiloride arm had a statistically significant mean
change in urate of 56.45 μmol/L (95 % CI: 53.37, 59.52)
in year one compared to year zero and a non-significant
change of −3.21 μmol/L (95 % CI: −6.48, 0.06) in year
two compared to year one. The differences in the
changes in urate between hydrochlorothiazide + amilor-
ide arm and placebo arm in year 1 vs. year 0 and year 2
vs. year 1 were statistically significant (mean difference
in changes of 53.10 μmol/L, 95 % CI: 49.35, 56.85 and of
−7.10 μmol/L, 95 % CI: −11.09, −3.10 respectively). In
the atenolol arm, there was a statistically significant
change in the mean urate in year one compared to year
zero of 43.00 μmol/l (95 % CI: 39.96, 46.04) and
4.81 μmol/L (95 % CI: 1.53, 8.10) in year two compared
to year one. The difference in the changes in urate be-
tween atenolol arm and placebo arm in year 1 vs. year 0
was statistically significant (mean difference in changes
39.65 μmol/L, 95 % CI: 35.93, 43.37) but not significant
between year 2 vs. year 1 (mean difference in changes of
0.93 μmol/L, 95 % CI: −3.08, 4.93). The difference be-
tween the hydrochlorothiazide + amiloride arm and aten-
olol arm changes was statistically significant in both
periods but not in the same direction: in year 1 vs. year
0, the mean difference (D-B) was 13.43 μmol/L, 95 % CI:
(9.10, 17.76), while in year 2 vs. year 1, the mean differ-
ence (D-B) was −8.02 μmol/L, 95 % CI: (−12.75, −3.30).
Discussion
The conduct of this trial has been described elsewhere: no
serious problems in terms of validity have been reported
[24, 26, 27]. As already noted, hydrochlorothiazide +
amiloride were shown to be more effective than atenolol
for prevention of stroke and MI [24]. Although the
hydrochlorothiazide + amiloride arm showed the great-
est drop-off in BP in the initial stage of the trial, both
active treatment groups reached similar average levels
after 2 years of follow-up [26]. Therefore, it was of interest
to see whether there was evidence that other metabolic
parameters - which could play a part in patient morbidity
and mortality - were affected by these treatments.
Given complete data arising from a randomised con-
trolled trial, ITT comparisons between randomised
groups allow us to estimate the causal effect of the
’intention to treat’ with a drug. However true efficacy
can be underestimated by ITT comparisons when there
is non-adherence or treatment cross-over as the trial
progresses. The ability to produce unbiased evidence
may also be compromised when there is missing data.
However, this issue is less problematic in the first year of
the trial: data was 83–90 % complete for all parameters
except glucose (77 %) at end of year one.
In the first year of the trial, patients in diuretic arm re-
ceived hydrochlorothiazide 25 mg or 50 mg plus amilor-
ide 2.5 mg or 5 mg daily [24]. Due to metabolic
disturbances observed among patients who were using
highest dose, all patients transferred to a lower dose
(hydrochlorothiazide 25 mg plus amiloride 2.5 mg).
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Some of the observed differences between year 1 and
year 2 changes among patients randomised in diuretic
arm might be explained by changes in dosage. Also
we would expect treatment supplementation may have
been more pronounced in the second year compared
to the first, thus blurring the contrasts between treat-
ment effects. These considerations suggest more em-
phasis is placed on the year one results, which we
now discuss in terms of changes relative to placebo
arm changes.
In the first year, hydrochlorothiazide + amiloride treat-
ments appeared to reduce sodium, weight and potassium
compared to placebo. The reduction in sodium that might
be attributed to the treatment, i.e. the difference between
hydrochlorothiazide + amiloride and placebo arm changes,
was substantial – on average, equivalent to 0.72 of base-
line SD (bSD). The beta-blocker, atenolol, also reduced so-
dium compared to placebo but to a lesser extent (0.29
bSD), and had little effect on weight i.e. weight gain (0.04
bSD). This combination of findings supports the previous
research which showed diuretic treatments being associ-
ated with weight losses rather than the beta blockers
which are known to be associated with weight gains
[10, 11, 31, 32]. The decrease in potassium attribut-
able to the hydrochlorothiazide + amiloride treatments
was non-trivial – equivalent to 0.46 bSD, while mean
potassium levels were increased by 0.19 bSD in the
atenolol group. The changes in serum potassium in
hydrochlorothiazide + amiloride group were in line
with findings from previous studies [33, 34]. Potassium-
sparing diuretics, despite not fully - are known to correct
the fall in serum potassium by increasing serum potas-
sium concentrations [35]. The impacts of beta blocker on
potassium match those observed in earlier studies and are
not of clinical importance [13, 36].
From the present data, it appeared that neither regi-
men affect glucose levels in the first year; this is surpris-
ing given a report elsewhere of withdrawal rates of 6.9,
5.8 and 2.7 per 1000 person-years -which we estimate as
4.0 %, 3.4 % and 1.5 % of patients - in hydrochlorothia-
zide + amiloride, atenolol and placebo arms respectively
for “impaired glucose tolerance” [24]. In our data, no pa-
tient in the hydrochlorothiazide + amiloride arm and
only one in the atenolol arm had a glucose level higher
than 7umol/L compared to eight in the placebo arm.
This incompatibility with results from the original report
suggests that our data may be incomplete and therefore
our results should be downplayed.
Cholesterol levels increased significantly over year
one in the hydrochlorothiazide + amiloride arm; mea-
sured against the change in the placebo group, the in-
crease attributable to treatment was of the order of
0.13 bSD; the atenolol arm also showed a significant
increase compared to placebo which again was rather
small (0.06 bSD). These findings differ from those ob-
tained by Lakshaman et al. which showed none of the
drugs had a long-term adverse effects on plasma lipids
and lipoprotein profiles in men with hypertension [37].
The increase in cholesterol levels in hydrochlorothiazide
+ amiloride arm is in accord with previous studies which
indicated relative increase in cholesterol level which varied
with dose and/or race [38, 39].
Both active treatments arms showed large increases in
mean urea and mean urate levels over year one, but the
increases for the hydrochlorothiazide + amiloride group
were significantly greater than in the atenolol group. For
urea, the increases were equivalent to 0.56 bSD and 0.39
bSD respectively, while for urate they were 0.75 bSD and
0.56 bSD. Other studies have shown consistent finding
that diuretic and beta blocker treatments gives similar
changes in kidney function [36, 39]. Increases in urate
levels associated with treatment with diuretics (but not
potassium-sparing diuretics) and beta blockers have
been reported previously [8, 18, 36, 40] and so results
here are not unexpected. Bengtsson has recommended
monitoring of serum uric acid levels after treatments
with diuretics [40]. However, in recent times, there has
been new debate [41–43], as to its significance for both
hypertension and cardiovascular disease: “an innocent
bystander” or a “central player”? Commenting on work
by Viazzi et al., which found that increased serum uric
acid (sUA) levels at baseline blunted the antihypertensive
impact 1.5 years later of lifestyle changes in children,
Bavish concluded that sUA is emerging “as a key factor
modulating hypertension”. Elsewhere [44], in an obser-
vational study based on the UK CPR Database, hyperten-
sive patients over 65 years with stable BP medication
who were also prescribed allopurinol showed a small re-
duction in SBP and DBP over time compared to com-
parable patients who were not, again suggesting a causal
role for sUA, although baseline sUA did not predict in
this study. In view of this and other evidence, the in-
crease in sUA in the hydrochlorothiazide + amiloride
and atenolol arms in this study are notable: perhaps BP
reduction might have been greater has there not been
concomitant increases in urate.
The key strengths of this study are its large sample
size, relative long follow-up and the use of sophisticated
statistical methods in analysis (LMM). This method of
statistical analysis uses all data from all patients includ-
ing those with an incomplete data schedule. Further-
more, the analysis involved estimation of changes within
and between treatment groups over time. Although pa-
rameters may not have changed sufficiently to warrant
withdrawal from the study for most patients, for scien-
tific reasons, it is important to understand the degree of
average change in the group, including when there is lit-
tle change. Indeed, results from large, well-powered
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studies, which show little change, are important for
demonstrating safety.
Despite being a multicentre study whereby measure-
ments were not performed in the same core laboratory
– the results of this study are not likely to be affected by
inter laboratory differences. The results which compare
the same patients at different time points (within-patient
comparisons) and comparisons between treatment
groups are not likely to be affected by inter labora-
tory differences in technique as we presume each
clinic used one laboratory and the same laboratory
was used for a given patient. Furthermore, randomisa-
tion to treatment groups was in stratified blocks
within each sex and clinic.
Our ‘intention to treat’ analysis followed the approach
of the original mortality study by comparing outcomes
by intended treatment, despite the treatment changes
within the treatment period. Such analyses are acknowl-
edged to address important pragmatic questions [45].
It might be argued that patient aged 65–75 are health-
ier today than 30 years ago but the evidence suggests
that deterioration is merely postponed: “indices of heath
that used to prevail at age 70 now prevail at age 80”
[46]. We believe that these results remain relevant to pa-
tients who present with systolic pressures of 160 mmHg
or more and who are prescribed similar drugs. As noted
in the Introduction, the US 2014 recommendations for
first line treatments continue to include thiazide type di-
uretics as well as beta blockers [5].
Conclusion
This study has shown that hydrochlorothiazide + amilor-
ide and atenolol treatments increase cholesterol, urea
and urate levels in a short period of time. Both active
treatments arms showed a significant decrease in sodium
levels over the first year of the trial. , No differences
were found in glucose levels among patients randomised
in hydrochlorothiazide + amiloride and atenolol arms
when compared to placebo arm.
Additional file
Additional file 1: Table S1. Mean (SD) of outcome variables over time
(all groups combined). (DOCX 12 kb)
Abbreviations
ACEs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor
blockers; bSD: Baseline standard deviation; CCBs: Calcium channel blockers;
CI: Confidence Interval; ITT: Intention-To-Treat; LMM: Linear mixed model;
MI: Myocardial Infarction; MRC: Medical Research Council; SD: Standard
deviation; SE: Standard error; UK: United Kingdom; US: United States
Acknowledgements
Although this work was not funded by them, we wish to acknowledge the
support of the UK Medical Research Council (Award No: R102506) for a
parallel project which inspired the present one.
Funding
None.
Availability of data and materials
Due to data agreements with the NHS Information Centre (reference
number MR28/MR28a), the supporting data is not openly available.
Authors’ contributions
DJD and RM designed the study. DJD, RM and MC analysed the data and
drafted the manuscript. DJD and RM interpreted the results. DJD and RM
contributed to the final draft of the manuscript. All authors gave their final
approval to the manuscript.
Authors’ information
DJD (BSc, MSc) - is a PhD fellow in the School of Public Health and Family
Medicine at the University of Cape Town, South Africa; a graduate at the
University of Manchester, UK and a Biostatistician at Kilimanjaro Christian
Medical Centre, Tanzania.
RM (BSc, MSc, PhD, FFOM) – is a Professor of Epidemiological Statistics in the
Centre for Biostatistics in the Institute of Population Health at the University
of Manchester, United Kingdom.
MC (BSc, MSc, PhD) – is a Biostatistician in the Centre for Mental Health and
Risk at the University of Manchester, United Kingdom.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Data agreement to allow further access to data was obtained in 2008 from
the NHS Information Centre (reference number MR28/MR28a). Further work
was funded by UK Medical Research Council (Award No: R102506) and the
specified work included examination of the longitudinal parameters.
Although the analyses in this paper were not directly funded, the objectives
overlap with those of the funded work for which data access was granted.
Received: 4 May 2016 Accepted: 28 September 2016
References
1. National Institute for Health and Care Excellence. Hypertension - Clinical
management of primary hypertension in adults. NICE clinical guideline.
2011. p. 127.
2. World Health Organization. Global health risks: Mortality and burden of
disease attributable to selected major risks. Bull World Health Organ. 2009;
87:646–6.
3. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, Farzadfar
F, Stevens GA, Lim SS, Riley LM, Ezzati M. Global Burden of Metabolic Risk
Factors of Chronic Diseases Collaborating Group (Blood Pressure). National,
regional, and global trends in systolic blood pressure since 1980: systematic
analysis of health examination surveys and epidemiological studies with 786
country-years and 5·4 million participants. Lancet. 2011;377:568–77.
4. Opie L, Schal R. Evidence-based evaluation of calcium channel blockers for
hypertension equality of mortality and cardiovascular risk relative to
conventional therapy. J Am Coll Cardiol. 2002;39:315–22.
5. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C,
Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC,
Svetkey LP, Taler SJ, Townsend RR, Wright JT, Navra AS, Ortiz E. 2014
evidence-based guideline for the management of high blood pressure in
adults: report from the panel members appointed to the Eighth Joint
National Committee (JNC 8). JAMA. 2014;311:507–20.
6. Redburn KA, Niebylski ML. Excellence and notable achievement awards
from the world hypertension league: a call for 2015 nominations. J Clin
Hypertens. 2014;16:927–9.
7. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use
and blood pressure control among united states adults with hypertension:
the national health and nutrition examination survey, 2001 to 2010.
Circulation. 2012;126:2105–14.
Damian et al. BMC Cardiovascular Disorders  (2016) 16:188 Page 8 of 9
8. Wilson L, Nair KV, Saseen JJ. Comparison of new-onset gout in adults
prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. J Clin
Hypertens (Greenwich). 2014;16:864–8.
9. Department of Veterans Administration. Veteran adminstration/department
of defence practise guidelines for diagnosis and management of
hypertension in the primary care setting. Washington D.C: Veteran
Adminstration and Department of Defence; 2004.
10. Davis BR, Davis BR, Oberman A, Blaufox MD, Wassertheil-Smoller S, Hawkins
CM, Cutler JA, Zimbaldi N, Langford HG. Effect of antihypertensive therapy
on weight loss. The trial of antihypertensive interventions and management
research group. Hypertension. 1992;19:393–9.
11. Freis ED, Reda DJ, Materson BJ. Volume (weight) loss and blood pressure
response following thiazide diuretics. Hypertension. 1988;12:244–50.
12. Pollare T, Lithell H, Berne C. A comparison of the effects of
hydrochlorothiazide and captopril on glucose and lipid metabolism in
patients with hypertension. N Engl J Med. 1989;321:868–73.
13. Sica SA. Antihypertensive therapy and its effects on potassium homeostasis.
J Clin Hypertens. 2006;8:67–73.
14. Doi Y, Aoi W, Suzuki S, Seto S, Baba K, Yano K. Changes in total body
potassium during long-term thiazide treatment: Effects of potassium
supplements on total body and serum potassium in hypertensive patients
with thiazide treatment. Int J Angiol. 1994;3:142–7.
15. Chrysant SG, Neller GK, Dillard B, Frohlich ED. Effects of diuretics on lipid
metabolism in patients with essential hypertension. Angiology. 1976;27:707–11.
16. Andreucci VE, Del Canton A (eds.). Diuretics: Basic, Pharmacological, and
Clinical Aspects: Proceedings of the International Meeting on Diuretics,
Sorrento, Italy, May 26–30, 1986. Naples: Springer Science & Business Media; 2012.
17. Hwang KS, Kim G-H. Thiazide-induced hyponatremia. Electrolyte Blood
Press. 2010;8:51–7.
18. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident
gout: a population-based case-control study. Arthritis Rheumatol (Hoboken,
NJ). 2014;66:185–96.
19. Wofford MR, Andrew ME, Brown A, King D, Pickett RA, Stevens J, Wyatt S,
Jones DW. Obesity hypertension in the atherosclerosis risk in communities
cohort: implications of obesity guidelines. J Clin Hypertens (Greenwich).
1999;1:27–32.
20. Aksnes TA, Kjeldsen SE, Mancia G. The effect of antihypertensive agents on
new-onset diabetes mellitus: time to amend the guidelines? Am J
Cardiovasc Drugs. 2006;6:139–47.
21. Lindholm L, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O.
Metabolic outcome during 1 year in newly detected hypertensives: results
of the Antihypertensive Treatment and Lipid Profile in a North of Sweden
Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563–74.
22. Ramsay LE, Yeo WW, Jackson PR. Diabetes, impaired glucose tolerance and
insulin resistance with diuretics. Eur Heart J. 1992;13(Suppl G):68–71.
23. Lindholm LH, Carlberg B, Samuelsson O. Beta blockers in primary hypertension:
Do age and type of beta-blocker matter? J Hypertens. 2006;24:2143–5.
24. MRC Working Party. Medical Research Council trial of treatment of
hypertension in older adults: principal results. MRC Working Party. BMJ.
1992;304:405–12.
25. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the
treatment of hypertension: a meta-analysis. CMAJ. 2006;174:1737–42.
26. Carr MJ, Bao Y, Pan J, Cruickshank K, McNamee R. The predictive ability of
blood pressure in elderly trial patients. J Hypertens. 2012;30:1725–33.
27. Lever AF, Brennan PJ. MRC trial of treatment in elderly hypertensives. Clin
Exp Hypertens. 1993;15:941–52.
28. Mancia G, Sega R, Milesi C, Cessna G, Zanchetti A. Blood-pressure control in
the hypertensive population. Lancet. 1997;349:454–7.
29. Street Edith. 17th expert committee on the selection and use of essential
medicines. Geneva: World Health Organization; 2009.
30. Narkiewicz K, Kjeldsen SE, Oparil S, Hedner T. Beta-blockers as sub-optimal
treatment for hypertension: time for first-line therapy revision? Blood Press.
2006;15:323–4.
31. Meiner S. Gerontologic Nursing. Maryland Heights: Elsevier Mosby. 2014.
32. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: -adrenergic
receptor blockers and weight gain : a systematic analysis. Hypertension.
2001;37:250–4.
33. Poulsen L, Friberg M, Noer I, Krusell L, Pedersen OL. Comparison of
indapamide and hydrochlorothiazide plus amiloride as a third drug in
the treatment of arterial hypertension. Cardiovasc Drugs Ther. 1989;3:
141–4.
34. Leppla D, Browne R, Hill K, Pak CYC. Effect of amiloride with or without
hydrochlorothiazide on urinary calcium and saturation of calcium salts. J
Clin Endocrinol Metab. 1983;57:920–4.
35. Morgan DB, Davidson C. Hypokalaemia and diuretics: an analysis of
publications. Br Med J. 1980;280:905–8.
36. Messerli FH (ed.). Kidney in Essential Hypertension: Proceedings of the
Course on the Kidney in Essential Hypertension held at New Orleans,
Louisiana, March 18–19, 1983. Springer Science & Business Media. 2012.
37. Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ED. Diuretics and
beta-blockers do not have adverse effects at 1 year on plasma lipid and
lipoprotein profiles in men with hypertension. Department of Veterans
Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern
Med. 1999;159:551–8.
38. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on
serum lipids. Ann Intern Med. 1995;122:133–41.
39. Savage PJ. Influence of Long-term, Low-Dose, Diuretic-Based, Antihypertensive
Therapy on Glucose, Lipid, Uric Acid, and Potassium Levels in Older Men and
Women With Isolated Systolic HypertensionThe Systolic Hypertension in the
Elderly Program. Arch Intern Med. 1998;158:741.
40. Bengtsson C. Elevated serum uric acid levels during treatment with
antihypertensive drugs. Acta Med Scand Suppl. 1979;628:69–71.
41. Kanbay M, et al. Uric acid in metabolic syndrome: From an innocent
bystander to a central player. Eur J Intern Med. 2016;29:3–8.
42. Bavishi C, Messerli FH, Rimoldi SF. Serum uric acid in primary hypertension.
Hypertension. 2016;67:845–7.
43. Viazzi F, et al. Increased serum uric acid levels blunt the antihypertensive
efficacy of lifestyle modifications in children at cardiovascular risk. Hypertens
(Dallas, Tex 1979). 2016;67:934–40.
44. Beattie CJ, et al. Allopurinol initiation and change in blood pressure in older
adults with hypertension. Hypertens (Dallas, Tex 1979). 2016;64:1102–7.
45. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of
published randomised controlled trials. BMJ. 1999;319:670–4.
46. Vaupel JW. Biodemography of human ageing. Nature. 2010;464:536–42.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Damian et al. BMC Cardiovascular Disorders  (2016) 16:188 Page 9 of 9
